Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease

Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease

Abstract Objectives: Chronic obstructive pulmonary disease (COPD) is the most common co-morbidity associated with non-small cell lung cancer (NSCLC) patients. Immune checkpoint inhibitors related pneumonitis (CIP) is a common immune-related adverse event that can be life-threatening. The study aims...

Full description

Bibliographic Details
Main Authors: Zhu Zeng, Jingjing Qu, Yake Yao, Fei Xu, Shan Lu, Pei Zhang, Yinan Yao, Ning Li, Jianying Zhou, Yuehong Wang
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Pulmonary Medicine
Subjects:
Checkpoint inhibitors related pneumonitis
Chronic obstructive pulmonary disease
Immune-related adverse events
Immune checkpoint inhibitors
Lung cancer
Online Access:https://doi.org/10.1186/s12890-022-02190-w

Internet

https://doi.org/10.1186/s12890-022-02190-w

Similar Items